Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Rhea-AI Summary

Solid Biosciences (Nasdaq: SLDB) announced that Bo Cumbo, President and CEO, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 10:30 AM ET. A live webcast will be available on the company Investor Events page, with a replay archived for 30 days.

Key Figures

Summit date: February 12, 2026 Presentation time: 10:30 AM ET Webcast replay period: 30 days

3 metrics

Summit date February 12, 2026 Guggenheim Emerging Outlook: Biotech Summit 2026 presentation date

Presentation time 10:30 AM ET Scheduled time for Guggenheim summit presentation

Webcast replay period 30 days Replay available on company’s Events page

Market Reality Check

Price: $6.52 Vol: Volume 1,450,359 is 35% a...

normal vol

$6.52 Last Close

Volume Volume 1,450,359 is 35% above the 20-day average of 1,072,183 ahead of the summit update. normal

Technical Shares at $6.23 are trading above the 200-day MA of $5.21 and about 15% below the 52-week high.

Peers on Argus

SLDB fell 4.45% while several close biotech peers also traded lower (e.g., LXRX ...

SLDB fell 4.45% while several close biotech peers also traded lower (e.g., LXRX down 11.28%, AURA down 3.93%, DMAC down 3.95%, FULC down 3.05%), but no coordinated sector momentum signal appeared in the scanner.

Historical Context

5 past events · Latest: Jan 13 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 13	2026 outlook update	Positive	-1.5%	Outlined 2026 outlook and clinical momentum across neuromuscular and cardiac programs.
Jan 12	Regulatory designation	Positive	-0.9%	Announced FDA Orphan Drug designation and existing Fast Track and Rare Pediatric status.
Jan 12	Clinical trial dosing	Positive	-0.9%	Dosed first participant in Phase 1b FALCON trial for SGT-212 in Friedreich’s ataxia.
Jan 06	Conference presentation	Positive	+3.0%	Announced J.P. Morgan Healthcare Conference presentation with webcast access for investors.
Jan 05	Inducement equity grant	Negative	-2.2%	Reported inducement grant of 7,000 RSUs to a new employee under stock plan.

Pattern Detected

Recent positive pipeline and designation updates have often been followed by modest share price declines, while conference-related appearances and routine equity grants have seen mixed reactions.

Recent Company History

Over the past month, SLDB has reported multiple pipeline milestones and corporate events. A 2026 outlook and several neuromuscular and cardiac program updates, including orphan and other FDA designations plus initial dosing in the FALCON trial, were followed by small share price declines. By contrast, a J.P. Morgan conference presentation on Jan 13 coincided with a 3% gain. An inducement RSU grant on Jan 5 saw a modest pullback, framing today’s Guggenheim summit appearance within an active news period.

Market Pulse Summary

This announcement highlights SLDB’s participation in the Guggenheim Emerging Outlook: Biotech Summit...

Analysis

This announcement highlights SLDB’s participation in the Guggenheim Emerging Outlook: Biotech Summit 2026, with management presenting on February 12, 2026 at 10:30 AM ET. It extends recent visibility efforts that included a major healthcare conference and multiple neuromuscular and cardiac program updates. Investors may watch for any new clinical, regulatory, or strategic details shared during the webcast, which will remain available for 30 days on the company’s site.

Key Terms

neuromuscular, cardiac

2 terms

neuromuscular medical

"developing precision genetic medicines for neuromuscular and cardiac diseases"

Relating to the connection and interaction between nerves and muscles, neuromuscular describes how signals from the nervous system make muscles move and function. For investors, neuromuscular issues and treatments matter because they drive demand for drugs, devices and diagnostic tests, shape development timelines and regulatory risks, and can change long-term revenue prospects in healthcare—think of it like the wiring and motors in a machine where problems or fixes affect overall performance and value.

cardiac medical

"developing precision genetic medicines for neuromuscular and cardiac diseases"

Relating to the heart; used to describe conditions, tests, treatments or devices that involve the heart’s structure or function. Investors track cardiac news because changes in heart-related trial results, regulatory approvals, device sales, or treatment costs can quickly alter a healthcare company’s revenue, expenses and risk profile—like how a problem with an engine affects the value and reliability of an entire car.

AI-generated analysis. Not financial advice.

CHARLESTOWN, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 10:30 AM ET.

A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.

About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic neuromuscular and cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com

Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com

FAQ

When will Solid Biosciences (SLDB) present at the Guggenheim Emerging Outlook: Biotech Summit 2026?

Bo Cumbo will present on Thursday, February 12, 2026 at 10:30 AM ET. According to the company, the presentation is part of the Guggenheim Emerging Outlook: Biotech Summit and is scheduled as a live, investor-facing session with web access.

How can investors watch the Solid Biosciences (SLDB) presentation on February 12, 2026?

Investors can watch a live webcast via the company Investor Events page or the provided webcast link. According to the company, the live stream will be available on the Events page of the Investors section of the company website.

Will Solid Biosciences (SLDB) make a replay of the Guggenheim presentation available?

Yes, a replay will be archived for 30 days after the live presentation. According to the company, the webcast replay will be available on the Events page of the Investors section for 30 days following the event.

Who will present for Solid Biosciences (SLDB) at the Guggenheim Biotech Summit 2026?

Bo Cumbo, President and CEO of Solid Biosciences, will deliver the presentation. According to the company, Cumbo will represent Solid and present company updates during the Guggenheim Emerging Outlook: Biotech Summit session.

What should investors expect from Solid Biosciences (SLDB) at the February 12, 2026 presentation?

Investors should expect an executive presentation by the company outlining recent developments and outlook. According to the company, the session is a standard investor presentation delivered at the Guggenheim Emerging Outlook: Biotech Summit and will be webcast live.